Gain Therapeutics reports CNS target engagement with GCase substrate reduction.

• CNS target engagement confirmed with reduction in GluSph in CSF • GluSph reduction indicates increased GCase activity in the brain • Expected to impact Parkinson’s disease progression • KOL event planned for early January • First-ever observation of GCase modulator in PD patients • Gain Therapeutics provided evidence of reduced GluSph in CSF • Registration information available for KOL event.